Across TCGA pan-cancer cohorts, OXT Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OXT data layer compared with 23 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OXT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OXT expression acts as an unfavorable survival marker.
HNSC are the cancer types where OXT Mutation most reproducibly stratifies survival.